REQUEST A DEMO
Total
USD $0.00
Search more companies

Ix Biopharma Ltd (Singapore)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Ix Biopharma Ltd Profile Updated: January 31, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company. It was formed in 2008 and acquired intellectual property rights for a formulation of a fentanyl citrate nasal spray for patient-controlled analgesia. The company's founder, Chairman, and CEO, Mr. Eddy Lee, assembled a team of scientists with extensive expertise in drug development. Their research focused on creating an innovative drug delivery system that would enhance the safety, efficacy, ease of use, and absorption rate of drugs compared to existing platforms and administration routes. Today, iX Biopharma is a publicly-listed company in Singapore, specializing in the development and commercialization of innovative therapies. Their main focus is on improving the quality of life for individuals suffering from pain and other health conditions. The company's main products under development include Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, and WafeRest for improved sleep quality. iX Biopharma operates in the United States, Singapore, Australia, and China, with the majority of its revenue coming from the United States.

Headquarters
20 Collyer Quay, 11-07
Singapore; Singapore; Postal Code: 049319

Contact Details: Purchase the Ix Biopharma Ltd report to view the information.

Website: http://www.ixbiopharma.com

Basic Information
Total Employees:
Purchase the Ix Biopharma Ltd report to view the information.
Outstanding Shares:
Purchase the Ix Biopharma Ltd report to view the information.
Financial Auditors:
Purchase the Ix Biopharma Ltd report to view the information.
Incorporation Date:
2004
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Chief Financial Officer
Purchase this report to view the information.
Director/Member of the Board
Purchase this report to view the information.
Secretary
Purchase this report to view the information.
Secretary
Ownership Details
Purchase this report to view the information.
23.21%
Purchase this report to view the information.
8.71%
Subsidiaries
Arrow Property Trust (Australia)
100%
Entity Health Pte Ltd
100%
Ix Biopharma Europe Limited
100%
Company Performance
Financial values in the chart are available after Ix Biopharma Ltd report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency SGD. Absolute financial data is included in the purchased report.
Net sales revenue
5.7%
Total operating revenue
-7.65%
Operating profit (EBIT)
34.82%
EBITDA
39.15%
Net Profit (Loss) for the Period
0.27%
Total assets
-29.08%
Total equity
-55.69%
Operating Profit Margin (ROS)
75.29%
Net Profit Margin
16.41%
Return on Equity (ROE)
-53.19%
Debt to Equity Ratio
56.96%
Quick Ratio
-0.56%
Cash Ratio
-0.59%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?